Clinical Trial Diversity Action Plan Waivers Will Be ‘Very Rare,’ US FDA Official Says

 
• By Nielsen Hobbs
Hundreds of diverse headshots
Sponsors should be prepared to check all the boxes on diversity action plans and not anticipate a waiver. • Source: Shutterstock

More from Diversity & Inclusion

More from Clinical Trials